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j ourna l homepage: www.e lsev ie r .com/ locate /atgWhat is translational bioinformatics?In 2001, the Human Genome Project successfully completed the ﬁrst
full human genome sequence (Lander et al., 2001; Venter et al., 2001).
With the advent of next generation sequencing (NGS) platforms, what
took over 3 billion dollars and more than 10 years to complete can
nowbedone for as little as $1000 and in only a fewdays. The application
of NGS has enabled for the interrogation of the human genome in ways
not previously considered. In recent years, large “big-data” projects
have utilized this technology to interrogate the human genome in ﬁnite
detail and provide valuable insights into themolecularmechanisms un-
derlying diseases. The 1000 genome project (Genomes Project C et al.,
2010, 2012) has revealed the diverse genetic variation across different
population groups. The ENCODE project (Consortium EP, 2012) identi-
ﬁed and characterized functional elements throughout the genome.
Similarly, The Cancer Genome Atlas (TCGA; http://cancergenome.nih.
gov/) has yielded valuable clues into the molecular biology of a variety
of cancers. Collectively, these studies and others have given new
clues to the genome that can ultimately be leveraged into clinical
applications.
While these large projects have not only taught us a lot of the nature
of the human genome, they have also generated newmethods to effec-
tively and efﬁciently mine the vast amount of data generated.With this
technology, the bioinformatics ﬁeld has ﬂourished and developed new
and complex ways to effectively and efﬁciently mine the data. Over
time, bioinformaticians have improved our ability to map the sequence
reads to the genome, and correlate the results to disease phenotypes,
and in some cases translate the results to a clinical setting (Chong
et al., 2015; Knoppers et al., 2015; Shen et al., 2015). Yet, our ability to
establish a better, more practical and accelerated path from discovery
to improved patient care lags. Certainly in the future, these, and future,
technologies will transform our approach to medicine and change the
ways in which we diagnose and treat diseases. But, in order for this to
be achieved new and speciﬁc tools to translate the genome to the clinic
are needed. A new ﬁeld, ‘translational bioinformatics’ is the domain to
bridge this gap.
The American Medical Informatics Association deﬁnes translational
bioinformatics as the development of storage, analytic and interpretive
methods to optimize the transformation of increasingly voluminous
genomic (proteomic, transcriptomic, metabolomic, epigenomic,
enviromic, interactomic, pharmacogenomic, phenomics) and biomedi-
cal data into proactive, predictive, preventive and participatory health
(https://www.amia.org/applications-informatics/translational-
bioinformatics). And in the past ten to ﬁfteen years, bioinformaticians
have largely devoted themselves to exactly these tasks: data analysis, li-
brary cataloging, database management, distribution specialization and
software engineering. While these tasks have well served certain trans-
lational needs, other new needs have evolved and the ﬁeld continues tohttp://dx.doi.org/10.1016/j.atg.2015.08.003
2212-0661/© 2015 The Authors. Published by Elsevier B.V. This is an open access article underadapt to these needs, aswell as deﬁne others. Currently, the transforma-
tion of huge volumes of complex data into clinically useful knowledge
requires the convergence molecular bioinformatics, biostatistics,
statistical genetics and clinical informatics into computational methods
to establish a better/more practical, and accelerated, path from discov-
ery to improving patient care, and important discoveries for practical
use. In other words, achieving these goals involves interdisciplinary
collaboration, and one that is essential to advancing translational geno-
mics, similar to those used in large “big data” research projects.
The importance of translational bioinformatics may be best under-
stood in the things it is teaching us, things not previously knowable.
For example, it is identifying ﬂawed science, improving estimates of rel-
ative pathogenicity of human genetic variants, inferring new insights
about underlying genetic mechanisms of disease, and identifying prom-
ising new drug indications based on curating large volumes of scientiﬁc
literature. While, sequencing an exome for a clinical diagnosis can be a
routine task, the interpretation of the data to make an actual diagnosis
or treatment plan is much more complex. Out of the many thousands
of variants identiﬁed, many of them will have to be evaluated for their
clinical utility. At times, for perhaps a simple Mendelian disorder this
may be as simple, as only a single variant will need to be identiﬁed
and considered. But for more complex diseases (e.g. cancers, diabetes,
or neurodegenerative diseases)multiple variants will need to be identi-
ﬁed. It is only by asking the correct questions about the patient and the
disease, alongwith employing the right computational tools that correct
answers can be achieved. In some cases appropriate questions and tools
already exist and can be applied, while in other cases, they still need to
be developed. Thus, the translational bioinformatics ﬁeld is poised to
address these issues and help generate the right answers.
Determining the right question to ask is now a collaborative effort
involving non-conventional sources. In the process, unaddressed areas
or unchallenged assumptions can be identiﬁed and so researched.
Bioniformaticians can, and for that matter do, create new tools to an-
swer the questions, pioneer and validate their use, and report ﬁndings
demonstrating the tool's ability to provide good answers. Thus, the
ﬁeld has moved from mere doing to also questioning and therefore to
being integrally involved in research design. In this way innovative bio-
informatics methods are revolutionizing translational science. Crowd
based discovery, newmethods for using genome/transcriptomes to rec-
ommend cancer treatments andmore trained systems, such asmachine
learning, are but some examples. Furthermore, it is our increasing abil-
ity to directly investigate that biological responses in real time is en-
abling the ﬁeld to understand the complexity of disease processes.
Thus, with the right questions and the right tools to answer them,
translational bioinformatics can translate DNA sequences into new dis-
coveries, novel diagnostics and fundamental causes of disease as targetsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2for new therapeutics. The scope of application, though, goes beyond the
biomedical sciences to health care delivery, health economy and health
policy. In this way, translational bioinformatics is crucial to advancing
translational genomics (omics).
In this special issue “What is Translational Bioinformatics?”we pres-
ent on overview papers that address some of the key questions in the
ﬁeld. Four articles address the need of improved tools and methods to
effectively transform genomic data into translatable results. In ‘The
problem with big data in translational medicine’, Jordan presents an
overview of the evolution of bioinformatics and look to the future of
translational medicine, while discussing current hindrances to applying
with big data techniques. In ‘Empowered Genome Community:
Leveraging a bioinformatics platform as a citizen-scientist collaboration
tool’, Wendelsdorf et al., discuss the potential research beneﬁts of a cit-
izen to researcher to citizen tool, highlighting how QIAGEN's ingenuity
platform and its ability to integrate clinical with the genomic data to op-
timally identify correlative variants can expedite research. Glazer et al.,
in ‘Atoms, Bits, and Cells’ shows how cloud computing can be leveraged
to increase the ability and speed atwhich genomic data can be analyzed.
Tobias et al., in ‘Developing educational iPhone, Android and Windows
smartphone cross-platform apps to facilitate understanding of clinical
genomics terminology’, present a simple and easy to use smartphone
app geared towards clinicians to aid in the interpretation of genomic
data. Finally, in ‘OncDRS: An Integrative Clinical and Genomic Platform
for Enabling Translational Research and Precision Medicine’, Methew,
et al., describe their OncDRS platform which can integrate clinical and
genomic data to enhance translational medicine and research. ‘Genome
Interpretation: clinical correlation is recommended’ by Segal discusses
differentways to clinically correlate genomic information. In ‘Interdisci-
plinary training to build an informatics workforce for Precision Medi-
cine’, Williams et al., present a model for a collaborative approach to
the training of future bioinformaticians and clinicians to better imple-
ment precision medicine. Two papers by Karikari et al., ‘Developing
expertise in bioinformatics for biomedical research in Africa’ and Wid-
eningparticipationwould be key in enhancing bioinformatics and geno-
mics research in Africa’, discuss the need for translational bioinformatics
in Africa, and speciﬁcally how the ﬁeld can enable knowledge genera-
tion by under-represented populations and in particular Africa. Theyshow this both in terms of the development of the infrastructure of ge-
nome centers and the need to increase the education of bioinformatic
researchers. Isaacson Barash, et al., in TranSMART Foundation Datathon
1.0: The Cross Neurodegenerative Diseases Challenge, present the suc-
cess of a datathon in neurodegenerative diseases; across Alzheimer's
disease, Parkinson's disease and others and the preliminary new ﬁnd-
ings it generated. Together, these articles display awindow into the var-
ious types of research questions and clinical needs important to the
translational bioinformatics ﬁeld, which can ultimately help bridge the
gap between genomics and an effective clinical utility.
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